| scholarly article | Q13442814 |
| P50 | author | Donna M MacCallum | Q55743468 |
| Frank C. Odds | Q88843128 | ||
| P2093 | author name string | Julie A Whyte | |
| P2860 | cites work | In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates | Q28345261 |
| Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus | Q30984430 | ||
| Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. | Q33968840 | ||
| Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits | Q33981480 | ||
| Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate | Q33983618 | ||
| Rationale for combination antifungal therapy | Q34335236 | ||
| Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). | Q34749364 | ||
| Voriconazole: a new triazole antifungal agent | Q35069136 | ||
| Caspofungin: first approved agent in a new class of antifungals | Q35124726 | ||
| Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. | Q35219729 | ||
| Combinations of antifungal agents in therapy--what value are they? | Q35890888 | ||
| In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus | Q36492208 | ||
| Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys | Q37121115 | ||
| Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species | Q37157546 | ||
| Effect of grapefruit juice on serum voriconazole concentrations in the mouse | Q39224290 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. | Q39652771 | ||
| Multidrug resistance in Aspergillus fumigatus. | Q44261807 | ||
| Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus | Q44418762 | ||
| The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human | Q44447139 | ||
| Invasive aspergillosis: current and future challenges in diagnosis and therapy | Q44714017 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| Synergy, antagonism, and what the chequerboard puts between them | Q73521098 | ||
| A rapid HPLC assay for voriconazole in human plasma | Q77506371 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| voriconazole | Q412236 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 3697-3701 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis | |
| P478 | volume | 49 |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q37263780 | Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions |
| Q38232492 | Antifungal combination therapy for invasive aspergillosis |
| Q35663841 | Antifungal pharmacokinetics and pharmacodynamics |
| Q43592326 | Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user |
| Q84765624 | Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei |
| Q38102782 | Combination antifungal therapy for invasive fungal infections in children and adults |
| Q28727508 | Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis |
| Q37190801 | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin |
| Q44619968 | Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus |
| Q35840760 | Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model |
| Q33517581 | Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillu |
| Q35113648 | Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies |
| Q37558822 | Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species |
| Q79300228 | Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q37123394 | Fungicidal versus Fungistatic: what's in a word? |
| Q38173720 | High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events |
| Q51186226 | High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. |
| Q37263430 | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates |
| Q42432990 | Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography |
| Q43718029 | Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study |
| Q35642204 | Newer combination antifungal therapies for invasive aspergillosis. |
| Q47434555 | Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates |
| Q33689767 | Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization. |
| Q35091545 | Standardization of an experimental murine model of invasive pulmonary aspergillosis |
| Q36788428 | The pharmacology and clinical use of caspofungin |
| Q37767359 | Use of Antifungal Combination Therapy: Agents, Order, and Timing |
| Q36729599 | Voriconazole : a review of its use in the management of invasive fungal infections |
| Q31129662 | [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience]. |
Search more.